What insurance policy changes affect code B07.0?

There are 8 tracked policy changes affecting code B07.0, including updates from Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code B07.0?

Payers that have issued tracked updates for code B07.0 include: Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code B07.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code B07.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code B07.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

B07.0 Insurance Policy Changes

ICD-10 B07.0 is officially defined as "Plantar wart." code B07.0 is referenced in 8 tracked payer policy changes from Independence Blue Cross, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code B07.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Apr 1, 2026Medium impact
MA11.071b, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)
Independence Blue Cross reissued MA11.071b on 04/01/2026 to reaffirm its coverage position on selective photothermolysis using pulsed-dye lasers (PDL). The policy clarifies that PDL treatment for psoriasis, molluscum contagiosum, basal cell carcinoma, cutaneous lupus erythematosus, and cutaneous sarcoidosis remains experimental/investigational and non-covered. The policy also updated criteria for rosacea treatment to align with current clinical standards and added specific ICD-10 diagnosis codes for non-covered indications.
Independence Blue Cross · Effective Apr 1, 2026Medium impact
11.08.04i, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)
Independence Blue Cross reissued Policy 11.08.04i on 04/01/2026 reaffirming its continuing position on PDL treatment coverage. The policy clarifies medically necessary indications (port wine stains, hemangiomas, hypertrophic/keloidal scars, pyogenic granulomas, viral warts, and rosacea), designates specific conditions as experimental/investigational (psoriasis, molluscum contagiosum, basal cell carcinoma, cutaneous lupus), and updates rosacea treatment criteria to require 6-month failed medical management before PDL coverage. Billing teams must verify patient diagnoses against the expanded ICD-10 code list and confirm medical necessity documentation for rosacea cases.
Aetna · Identified Oct 1, 2026Medium impact
Pulsed Dye Laser Treatment (CPB 0559, reviewed 2026-09-18)
Aetna's Clinical Policy Bulletin 0559 covers pulsed dye laser treatment. It considers the pulsed dye laser medically necessary for conditions including actinic keratoses that have not adequately responded to imiquimod, 5-FU or cryosurgery, infantile hemangiomas, port wine stains and hemangiomas on the face and neck, and verrucae after at least two conventional therapies have failed. It considers the laser experimental, investigational or unproven for other indications such as active acne, onychomycosis and non-melanoma skin cancer, and cosmetic for conditions such as rosacea, solar lentigines and striae distensae.
Aetna · Identified Aug 19, 2026Medium impact
YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)
Aetna considers Nd:YAG laser capsulotomy medically necessary after cataract extraction in members with visually significant clouding of the posterior capsule, and considers Nd:YAG laser peripheral iridotomy medically necessary for acute primary angle closure, primary angle-closure glaucoma, plateau iris syndrome, aqueous misdirection, and before intraocular lens insertion into the anterior chamber to avoid post-operative iris bombe or pupil block. Capsulotomy performed within 6 months of cataract surgery is subject to medical necessity review, and it is considered experimental, investigational, or unproven if none of the stated criteria is met. Nd:YAG laser vitreolysis for vitreous floaters, posterior hyaloidotomy for pre-macular hemorrhage, goniopuncture for failed trabeculectomy, and peripheral iridotomy to prevent pigment dispersion glaucoma are considered experimental, investigational, or unproven, as are many non-ophthalmological uses such as basal cell carcinoma, benign prostatic hyperplasia, onychomycosis and snoring.
Aetna · Identified Aug 15, 2026Medium impact
Carbon Dioxide Laser (CPB 0427, reviewed 2026-07-08)
Aetna's clinical policy bulletin for carbon dioxide laser (CPB 0427) lists the uses it considers medically necessary: condyloma, pelvic pain associated with endometriosis, primary penile tumors (clinical stage Tis, Ta, and T1 Grade 1 to 2), refractory plantar warts, removal of actinic keratoses for members who meet CPB 0567 criteria, removal of superficial basal cell carcinomas, and fractional carbon dioxide laser for hypertrophic burn, traumatic, and surgical scars when conventional therapies have failed. Aetna considers carbon dioxide laser experimental, investigational, or unproven for a list of other indications, including hidradenitis suppurativa, male androgenetic alopecia, onychomycosis, port wine stains, stress urinary incontinence, and vaginal atrophy. Aetna considers carbon dioxide laser treatment of other actinic lesions cosmetic.
Aetna · Identified Aug 14, 2026Medium impact
Pulsed Dye Laser Treatment (CPB 0559, reviewed 2025-08-22)
Pulsed dye laser treatment is medically necessary for actinic keratoses that failed to adequately respond to imiquimod, 5-FU, or cryosurgery, for capillary malformation with overgrowth or vascular malformation, for genital warts when home therapy with podophyllotoxin or imiquimod has failed, for granuloma faciale, for infantile hemangiomas, and for port wine stains and other hemangiomas on the face and neck. It is also medically necessary for keloids or hypertrophic scars from an injury or surgical procedure that cause significant pain requiring chronic analgesic medication or significant functional impairment, for multiple superficially located glomangiomas in the face and neck where surgical excision is not practical, for pyogenic granuloma in the face and neck, for symptomatic angiolymphoid hyperplasia that has failed medical therapy, and for verrucae after at least two conventional therapies have failed. Pulsed dye laser is considered experimental, investigational, or unproven for other conditions, including active acne, onychomycosis, hidradenitis suppurativa, molluscum contagiosum, and morphea, and cosmetic for conditions including rosacea, facial redness, solar lentigines, and striae distensae.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Removal of Benign Skin Lesions and Scars
Cosmetic surgery and any complications of cosmetic surgery are not eligible for coverage, including any operative procedure or portion of one intended solely to improve physical appearance. Removal of seborrheic keratoses, sebaceous (epidermoid) cysts, nevi, papillomas and viral warts (excluding condyloma acuminatum) is medically necessary only when the lesion is symptomatic or has objective signs or symptoms listed in the policy, such as itching, burning, irritation, significant change in color or size or bleeding, physical evidence of inflammation, obstruction of an orifice or clinically restricted vision, clinical uncertainty about malignancy, a prior biopsy indicative of malignancy, or recurrent physical trauma that is documented to have occurred. Removal for reasons such as emotional distress, "makeup trapping" or location alone is considered cosmetic and not medically necessary.
Aetna · Identified Nov 4, 2026Low impact
Microwave Thermotherapy (CPB 0682, reviewed 2026-10-26)
Aetna's Microwave Thermotherapy policy (CPB 0682) was reviewed on 2026-10-26, and the source does not state what changed or give a new effective date. It covers microwave thermotherapy as medically necessary only for T1 renal lesions, medically inoperable non-small cell lung cancer lesions under 3 cm, and hepatocellular carcinoma tumors of 3 cm or less, and it lists many other uses (such as breast, pancreatic, bladder, and chronic pain indications) as experimental, investigational or unproven.

Watch B07.0

Get one email when a payer policy names B07.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA11.071b, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)

11.08.04i, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)

Pulsed Dye Laser Treatment (CPB 0559, reviewed 2026-09-18)

YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)

Carbon Dioxide Laser (CPB 0427, reviewed 2026-07-08)

Pulsed Dye Laser Treatment (CPB 0559, reviewed 2025-08-22)

Removal of Benign Skin Lesions and Scars

Microwave Thermotherapy (CPB 0682, reviewed 2026-10-26)

What insurance policy changes affect code B07.0?

Which payers have updated policy for code B07.0?

How do I get notified when code B07.0 policy changes?

Why do payers change policies for code B07.0?